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RLate Gadolinium Enhancement
and Higher Risk of Arrhythmias
Fibrosis or Increased
Ventricular Wall Stress?
Current criteria indicating implantable cardioverter-defibrillator
(ICD) therapy for primary prevention of sudden cardiac death are
poor, and non–evidence-based ICD implantations are more likely
to have worse outcomes. Therefore, Iles et al. (1) examined late
gadolinium enhancement (LGE) by using cardiac magnetic reso-
nance imaging to predict appropriate device therapy in patients
with ischemic and nonischemic cardiomyopathy. The study relies
on the assumptions that myocardial fibrosis is the substrate of
LGE and that fibrosis is associated with arrhythmias.
Well-documented links between fibrosis and LGE exist in
patients who have experienced myocardial infarction in whom
nonviable cardiomyocytes are replaced by collagen. This contigu-
ous subendocardial or transmural area can be detected by a bright
LGE pattern. Histological changes are very different in patients
with dilative cardiomyopathies. Histopathological studies have
shown that the myocardial remodeling can be associated with an
increased collagen volume fraction, and in transmural left ventric-
ular sections, the extent of fibrosis increased from epicardium to
endocardium and from the right to the left side of the septum (2).
LGE occurs as midwall (septal) streak (1) or is irregularly diffuse.
Thus, in dilative cardiomyopathies, causes beyond fibrosis should
be taken into account for LGE.
In the study by Iles et al. (1), all patients with ischemic
cardiomyopathy exhibited LGE, and the ICD discharge rate was
14%, whereas it was 29% in patients with nonischemic cardiomy-
opathy and LGE. Also, based on the absence of differences in left
ventricular ejection fraction and end-diastolic volume index, it was
concluded that fibrosis predicts appropriate ICD therapy. How-
ever, it remains to be assessed whether indeed fibrosis or an
increased wall stress was responsible for LGE and ICD therapy.
Using echocardiography-based ventricular mass and geometry
data, we suggest calculating wall stress and examining the conten-
tion that patients with ICD therapy exhibit increased wall stress.
In accordance with a role of wall stress for LGE, our recent
study on 300 patients with dilative cardiomyopathy showed that a
rise in wall stress (3) was associated with LGE (4). Most likely,
higher wall stress is associated with an increased capillary leakage,
and thus favors contrast medium emission into the interstitial
space. Also, its venous clearance can be prolonged by an impaired
redistribution. The link of LGE with arrhythmias would follow
from experimental studies in which myocardial stretch and neuro-
humoral reactions predispose patients to arrhythmias involving, for
example, stretch-activated cation channels.
The proposed subanalysis also could clarify whether LGE per se
is an independent prognostic predictor or a dependent surrogatemarker. Thus, in a study of 141 patients with dilated cardiomy-
opathy, the prognostic value of LGE regarding survival was found
only by univariate, but not by multivariate, analysis (5). Increased
wall stress thus could be the underlying mechanism of a worse
prognosis and should be evaluated also as indicator for ICD
therapy.
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Reply
Drs. Alter and Rupp propose that late gadolinium enhancement
(LGE) in nonischemic cardiomyopathy may be the result of
increased myocardial wall stress with resultant increased capillary
permeability and reduced venous return.
In our study (1), patients without LGE did not experience
implantable cardioverter-defibrillator discharges, suggesting that
this group may be at lower risk for malignant ventricular arrhyth-
mia. LGE previously was demonstrated to correlate well with
ischemic regional fibrosis (2) and also in limited human studies in
nonischemic pathological conditions (3). Therefore, we postulated
the likely mechanism for implantable cardioverter-defibrillator
discharges in advanced cardiomyopathy to be the presence of
regional scar acting as an arrhythmogenic substrate. However,
regardless of the mechanism, a lack of LGE was associated with a
